Clinical trials: Treatment of HCV-infected patients with advanced kidney disease

Clinical trials: Treatment of HCV-infected patients with advanced kidney disease, Published online: 27 November 2017; doi:10.1038/nrneph.2017.161

Antiviral treatment options for HCV-infected patients with advanced kidney disease are limited because few clinical trials have tested the efficacy of antiviral drugs in this population. Now, a phase III trial of two pan-genotypic drugs demonstrates excellent viral clearance with minimal adverse events in HCV-infected patients with advanced kidney disease.

中文翻译：

---

临床试验：治疗HCV感染的晚期肾脏疾病患者

临床试验：治疗HCV感染的晚期肾脏疾病患者

临床试验：治疗HCV感染的晚期肾脏疾病患者，在线发布：2017年11月27日; doi：10.1038 / nrneph.2017.161

对于HCV感染的晚期肾脏疾病患者，抗病毒治疗的选择是有限的，因为很少有临床试验在该人群中测试过抗病毒药物的疗效。现在，两项泛基因型药物的III期试验显示，在患有HCV感染的晚期肾脏疾病患者中，病毒清除率极高，不良事件极少。